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A B S T R A C T
Although cancer-associated ﬁbroblasts (CAFs) are viewed as a promising therapeutic target, the design
of rational therapy has been hampered by two key obstacles. First, attempts to ablate CAFs have re-
sulted in signiﬁcant toxicity because currently used biomarkers cannot effectively distinguish activated
CAFs from non-cancer associated ﬁbroblasts andmesenchymal progenitor cells. Second, it is unclear whether
CAFs in different organs have different molecular and functional properties that necessitate organ-
speciﬁc therapeutic designs. Our analyses uncovered COL11A1 as a highly speciﬁc biomarker of activated
CAFs. Using COL11A1 as a ‘seed’, we identiﬁed co-expressed genes in 13 types of primary carcinoma in
The Cancer Genome Atlas. We demonstrated that a molecular signature of activated CAFs is conserved
in epithelial cancers regardless of organ site and transforming events within cancer cells, suggesting that
targeting ﬁbroblast activation should be effective in multiple cancers. We prioritized several potential
pan-cancer therapeutic targets that are likely to have high speciﬁcity for activated CAFs and minimal tox-
icity in normal tissues.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Under normal physiological conditions, collagen-rich ﬁbro-
blasts maintain tissue architecture and serve as a barrier to epithelial
cell migration. However, cancer cells have the ability to convert
the surrounding ﬁbroblasts into activated CAFs, which secrete spe-
ciﬁc collagens, growth factors, and enzymes that promote cancer
growth, angiogenesis, invasion, and metastasis [1–3]. At the same
time, these CAFs suppress anticancer immunity, confer drug resis-
tance and/or limit the access of chemotherapies, anti-angiogenic
therapies, and immunotherapies [1–3]. Although the exact mecha-
nisms by which activated CAFs contribute to such diverse aspects
of cancer progression are unclear, it is thought that ﬁbroblasts
together with increased collagen deposition and altered extracel-
lular matrix (ECM) remodeling serve as a rich depot of cancer-
promoting growth factors, cytokines, and chemokines [1,2].
Additionally, altered levels of enzymes responsible for collagen
cross-link formation, such as lysyl oxidase (LOX) [4], increase tissue
stiffness and modify mechanotransduction resulting in the reorga-
nization of loose connective tissue into tense linear tracks of ﬁbers
that serve as highways to promote chemotaxis of cancer cells
[5,6].
Recognizing the crucial role of CAFs in most aspects of cancer
progression, it has been proposed that rational anticancer therapy
design should not only target the cancer cells but also the CAFs [7,8].
Unlike cancer cells, CAFs are genetically stable [9], which reduce the
risk of therapy-induced clonal selection, resistance, and cancer re-
currence. Furthermore, targeting CAFs could potentially affect
multiple biochemical pathways to prevent cancer progression
and recurrence. CAF-targeting therapeutic approaches in different
experimental mouse cancer models have been shown to improve
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tumoral immune response, intratumoral drug delivery, and thera-
peutic eﬃcacy [10–15]. These studies conﬁrm the key role of CAFs
in cancer progression and demonstrate their effectiveness as a ther-
apeutic target. However, targeting CAFs in some cancer models
actually promoted cancer progression. For example, depletion of
αSMA+ stroma in a mouse pancreatic cancer model resulted in in-
creased cancer aggressiveness, enhanced hypoxia and epithelial–
mesenchymal transition (EMT), suppressed anticancer immunity,
and reduced survival [16].
The contradictory results in different cancer models could be ex-
plained by different roles of CAFs in different cancer types, i.e. CAFs
could be promoting breast cancer and inhibiting pancreatic cancer.
Alternatively, in all cancer types CAFs prevent cancer progression
until they receive activating signals from cancer cells and convert
into ‘activated CAFs’, which in turn confer invasive and metastatic
abilities upon cancer cells [7]. Therapies that target all CAFs are coun-
terproductive and likely to result in the death of normal ﬁbroblasts
and signiﬁcant toxicity. Preferential targeting of activated CAFs has
been challenging because activated CAFs are poorly understood at
the molecular level. During activation, CAFs exhibit phenotypic
changes that partially overlap with myoﬁbroblastic changes during
wound healing, inﬂammation, and ﬁbrosis, including secretion of
speciﬁc ECM components, cytokines and growth factors [1,17].
Several markers have been used to distinguish activated from non-
activated CAFs: α-smooth muscle actin (αSMA, encoded by gene
ACTA2) [3], ﬁbroblast activation protein (FAP) [12], podoplanin
(PDPN) [18], palladin (PALLD) [19,20], tenascin-C (TNC) [21], platelet-
derived growth factor receptor α (PDGFRα) [22,23], and chondroitin
sulfate proteoglycan 4 (CSPG4) [24]. However, these markers are fre-
quently expressed in other cells within the cancer stroma, such as
vascular smoothmuscle cells, pericytes, andmesenchymal stem cells.
This lack of speciﬁcity could pose problems in therapeutic target-
ing and underscores the need to better understand the molecular
characteristics of activated CAFs in order to develop more precise
and less toxic targeted therapies.
COL11A1 encodes the α1 chain of collagen XI, a minor ﬁbrillar
collagen expressed by chondrocytes and osteoblasts but not qui-
escent ﬁbroblasts [25,26]. The absence of functional collagen XI leads
to abnormally thickened cartilage and tendon ﬁbrils, suggesting the
role of collagen XI in maintaining proper ﬁbril diameter [27,28].
Studies have demonstrated that COL11A1 mRNA is markedly el-
evated in cancers of the oral cavity/pharynx, head and neck, breast,
lung, esophagus, stomach, pancreas, colon, and ovary, but not in
matched normal tissues (reviewed in [25,26]). COL11A1 has been
identiﬁed as part of gene signatures associated with adverse clin-
ical outcomes including resistance to neoadjuvant therapy in breast
cancer [29], time to recurrence in glioblastoma [30], poor survival
in kidney cancer [31], and time to recurrence and overall survival
in ovarian cancer [32,33]. In situ hybridization in ovarian cancer
and immunohistochemistry in pancreatic cancer revealed that
COL11A1 mRNA and pro-protein are primarily expressed in CAFs
[25,32]. The restricted expression of COL11A1 in normal tissues and
its enrichment in CAFs during cancer progression combined with
its association with adverse clinical outcomes in multiple types of
cancer support its candidacy as a speciﬁc marker of ﬁbroblast ac-
tivation in diverse cancers. Here, we explore the suitability of COL11A1
as a pan-cancer marker of activated CAFs and use it as a ‘seed’ to
identify the transcription signature of activated CAFs in 13 epithe-
lial cancer types. We show that the COL11A1-coexpressed gene set
is highly conserved in these 13 cancer types, indicating that the ﬁ-
broblast reaction to cancer cells is independent of the organ site-
of-origin and of the transforming events within cancer cells. Finally,
by combining drug target databases with cancer vs. normal tissue
expression databases, we identify several potential therapeutic
targets that should have high speciﬁcity for activated CAFs and
minimal toxicity in normal tissues.
Materials and methods
Human tissues
Studies involving human tissue samples were approved by the Cedars-Sinai In-
stitutional Review Board (IRB 15425). The samples included a tissue microarray from
42 patients with matched primary, metastatic, and recurrent ovarian cancer.
In situ hybridization
The RNA hybridization kit (RNAscope 2.0 FFPE Assay) and probes for COL11A1,
the bacterial gene dapB (negative control), and the housekeeping gene HPRT (pos-
itive control), were from Advanced Cell Diagnostics, Inc. Formalin-ﬁxed, paraﬃn-
embedded tissue section slides were processed by the Cedars-Sinai Biobank and
Translational Research Core following the protocol provided with the RNAscope In
Situ Hybridization kit from Advanced Cell Diagnostics, Inc. The slides were coun-
terstained with Mayer’s hematoxylin.
Immunohistochemistry
Immunohistochemical detection of αSMA was performed on formalin-ﬁxed,
paraﬃn-embedded tissue sections using the protocol provided with the pre-
diluted asm-1 clone antibody from Leica Microsystems. Staining was done by the
Cedars-Sinai Pathology Service on the Ventana Benchmark Ultra automated slide
stainer. The stainingwas visualized using the Ventana OptiViewDABDetection System.
The slides were counterstained with Mayer’s hematoxylin.
In vitro co-culture experiments
The ovarian cancer cell lines OVCAR3-GFP, KURAMOCHI-GFP and OVSAHO-
GFP were maintained in RPMI-1640 (Corning) supplemented with 10% fetal bovine
serum (FBS) and 1x penicillin/streptomycin (Corning). Cell line authenticity was con-
ﬁrmed by Laragen using the short tandem repeat (STR) method. The immortalized
normal ovarian ﬁbroblasts INOF-tdTomato cell lines [34] were maintained in a 1:1
ratio of MCDB 105 (Sigma-Aldrich) and Medium 199 (GIBCO) with 10% FBS, 50 U/
ml penicillin and 50 μg/ml streptomycin. Immortalized normal ovarian ﬁbroblasts
and ovarian cancer cells were co-cultured in 1% FBS supplementedmedia (1:1:2 ratio
of MCDB 105, Medium 199 and RPMI-1640) using 6-well plates, either by directly
plating ovarian cancer cells (105 cells/well) onto a 70% conﬂuent layer of normal
ovarian ﬁbroblasts or onto a 0.4 μm Transwell membrane. Media were replaced every
2 days. After 4 days of co-culture, GFP-labeled ovarian cancer cells and tdTomato-
labeled ﬁbroblasts were separated by FACS in PBS with 0.5% FBS. RNA extraction from
ﬁbroblasts and ovarian cancer cell lines was performed using the RNeasy Mini Kit
(Qiagen) and reverse transcribed to cDNA using the Quantitect Reverse Transcrip-
tion Kit (Qiagen). For qRT-PCR, 50 ng of cDNA was mixed with COL11A1 primers
(Forward: 5′-GACTATCCCCTCTTCAGAACTGTTAAC-3′; Reverse: 5′- CTTCTATCAAGTGG
TTTCGTGGTTT-3′) and the iQ SYBR-Green Supermix (BioRad) and run on the CFX96
Real-Time System (BioRad). Data were analyzed using the 2-ΔCT method and nor-
malized to INOF-tdTomato control to present the fold change ratios. All mRNA data
were normalized to RPL32 expression (Forward: 5′-ACAAAGCACATGCTGCCCAGTG-
3′; Reverse: 5′-TTCCACGATGGCTTTGCGGTTC-3′). The statistical analyses were
performed using GraphPad Prism (version 6.0; GraphPad Software). The unpaired
t test was used for data analyses.
Public database portals and dataset analyses
Data from public portals were used as provided by individual portals without
additional processing or normalization, unless otherwise indicated. Box plots of
COL11A1 expression in normal tissues and cancers were generated using the Gene
Expression across Normal and Tumor tissue (GENT) portal (medical-
genome.kribb.re.kr/GENT) in which data frommultiple datasets were processed and
normalized as previously described [35]. COL11A1 expression level diagrams for in-
ﬂammatory bowel disease, lung ﬁbrosis, and cancers of the colon and lung were
generated using the R2 MegaSampler public portal (hgserver1.amc.nl/cgi-bin/r2/
main.cgi). A description of the methods used for data processing and normalization
is available through the portal. Survival z-scores for individual genes and cancer types
were obtained from the PREdiction of Clinical Outcomes from Genomic Proﬁles
(PRECOG) portal (precog.stanford.edu). Methods for calculating PRECOG z-scores have
been published [36]. Ranking of the COL11A1-correlated genes in 13 TCGA carcino-
ma types was determined using data from individual cancer datasets that were
processed by cBio Portal (cbioportal.org) as previously described [37]. Kaplan–
Meier survival plots and plots of COL11A1 expression in individual molecular subtypes
of ovarian carcinoma were generated using the ovarian cancer microarray gene ex-
pression database CSIOVDB (csibio.nus.edu.sg/CSIOVDB/CSIOVDB.html), which has
been previously described [38]. The dataset for ﬁbroblast and ovarian epithelial cell
co-culture was imported from the Gene Expression Omnibus (ncbi.nlm.nih.gov/
geo). The Euclidean distance clustering analysis heatmap for the e-mtab-991 [39]
and GSE40595 [40] datasets was generated using the public R2 GeneSet Clustering
Analysis portal (hgserver1.amc.nl/cgi-bin/r2/main.cgi), which also describes methods
that were used to process and normalize data from datasets included in the portal.
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Results
COL11A1 is expressed in a subset of αSMA-positive CAFs and can be
induced in normal ﬁbroblasts by the presence of cancer cells
To determine if COL11A1 expression is associated with ﬁbro-
blast activation, we used αSMA as a marker of activated CAFs [3].
Comparison of αSMA immunohistochemistry and COL11A1 in situ
hybridization in a tissue microarray consisting of primary, meta-
static and recurrent ovarian cancers from 42 patients showed that
COL11A1 is expressed in a subset of αSMA+ CAFs (Fig. 1A). Unlike
αSMA, COL11A1 was not expressed in blood vessels (red arrows) or
in ﬁbroblasts surrounding the cancer (blue arrows) (Fig. 1A).
In sections of metastatic ovarian cancer, we observed that
COL11A1-positive cells are conﬁned to the intratumoral and imme-
diate peritumoral CAFs (Fig. 1B), suggesting that COL11A1 expression
may be induced by cues received from epithelial cancer cells. To test
if cancer cells can induce COL11A1 expression in ﬁbroblasts, we
co-cultured immortalized normal ovarian ﬁbroblasts (INOFs) with
three different ovarian cancer cell lines (OVSAHO, OVCAR3, and
KURAMOCHI). COL11A1 expression in INOFs was most strongly
induced by direct co-culture with ovarian cancer cell lines al-
though weak induction occurred by indirect co-culture on a
Transwell membrane (Fig. 1C). The induction of COL11A1 in ﬁbro-
blasts in the presence of cancer cells was conﬁrmed by analysis
of the public expression dataset GSE52104 in which two types of
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Fig. 1. COL11A1 is expressed in CAFs. (A) Comparison of αSMA immunohistochemistry and COL11A1 in situ hybridization in a metastatic ovarian cancer sample. Red arrows
indicate blood vessels. Blue arrows indicate ﬁbroblasts surrounding the tumor nodule. A high magniﬁcation of peritumoral and intratumoral regions in the black rectangles
is shown in panels on the left. IHC, immunohistochemistry; ISH, in situ hybridization; BV, blood vessel; NC, necrosis. (B) Distribution of in situ hybridization COL11A1-
positive CAFs in relation to cancer cells. The estimated percent of COL11A1-positive CAFs is shown on the right. The image is representative of metastatic and recurrent
ovarian cancer samples, which typically express higher levels of COL11A1 than primary ovarian cancers. (C) Quantitative RT-PCR levels of COL11A1 in sorted (FACS) immor-
talized normal ovarian ﬁbroblasts (INOFs) grown alone or co-cultured with ovarian cancer cell lines (OVSAHO, OVCAR3, KURAMOCHI) that were either separated from INOFs
by a Transwell membrane or directly mixed with INOFs. Statistical analyses were performed between INOFs grown alone and INOFs co-cultured with ovarian cancer cells
(*p < 0.05; **p < 0.01; ***p < 0.001; ns, not signiﬁcant). Error bars indicate standard deviation. (D) Levels of COL11A1 in the GSE52104 expression dataset in which mesen-
chymal stem cells (MSCs) or immortalized normal ovarian ﬁbroblasts (INOFs) were either cultured alone or co-cultured with IOSE4 normal epithelial cells (IOSE) or HEYA8
epithelial ovarian cancer cells (EOC) using a Transwell membrane. Inverse-log2 values of the Robust Multi-array Average (RMA) scores from different COL11A1 probes were
averaged, then log2-transformed. The data were extracted for statistical analyses using GraphPad Prism 6. Data are represented as the mean ± SEM. Intergroup differences
were assessed by the Student’s t-test. *p < 0.05; ****p < 0.0001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version
of this article.)
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presumptive cancer-associated ﬁbroblast precursor cells, mesen-
chymal stem cells (MSCs) and immortalized normal ovarian
ﬁbroblasts (INOFs), were either cultured alone or co-cultured with
normal ovarian surface epithelial cells (IOSE) or epithelial ovarian
cancer cells (EOC) using a Transwell membrane [41]. COL11A1mRNA
was statistically signiﬁcantly upregulated when MSCs and INOFs
were co-cultured with EOC but not IOSE (Fig. 1D), indicating that
cancer cells have a greater capacity than normal cells to induce
COL11A1 expression in ﬁbroblasts.
COL11A1 is associated with cancer progression and poor survival
COL11A1 mRNA expression has been associated with poor sur-
vival in ovarian cancer [32,33] and kidney cancer [31]. To elucidate
the underlying biology that could result in poor survival, we inves-
tigated its expression in ovarian and colon cancers. Using a
comprehensively annotated microarray database for 3431 human
ovarian cancers [38], we show that increased expression of COL11A1
mRNA is associated with overall survival and disease-free survival
(Fig. 2A) as well as with clinical and molecular parameters such as
increased cancer stage and grade and mesenchymal molecular
subtype (Fig. 2B). The association of COL11A1 expression with poor
survival is unlikely to be a manifestation of the total amount of
stromal ﬁbroblasts because a general marker of ﬁbroblasts, vimentin
(VIM), is not associated with poor survival in the same cohort of
ovarian cancer patients (Table S1). The association of COL11A1 with
adverse outcomes is also not restricted to ovarian cancer. We show
that in 1820 colon cancers [42], increased expression of COL11A1
mRNA is associated with poor disease-speciﬁc and disease-free sur-
vival as well as with clinical and molecular parameters, such as
increased cancer stage andmicrosatellite instability and CMS4 (mes-
enchymal) molecular subtype (Fig. S1A, B).
To systematically investigate an association between COL11A1
mRNA expression and survival in various solid and liquid cancers,
we plotted COL11A1 z-score values as determined by the pan-
cancer PREdiction of Clinical Outcomes from Genomic Proﬁles
(PRECOG) analysis of ~18000 cases in 166 cancer datasets [36]. In
most epithelial cancers, COL11A1 expression was associated with
poor survival (Fig. 3A). Associations between expression of 43 col-
lagen genes and survival z-scores in 12 common epithelial cancer
types revealed that for the majority of collagens, increased expres-
sions of mRNA were associated with poor survival, with COL11A1
having the strongest association (Fig. 3B).
COL11A1 is among the most differentially expressed genes between
cancers and corresponding benign tissues
In the Genotype-Tissue Expression (GTEx) project database [43],
COL11A1 mRNA is expressed at appreciable levels in transformed
skin ﬁbroblasts but not in non-transformed skin ﬁbroblasts or other
normal tissues (Fig. S2). Additional analyses of various expression
datasets containing normal adult mouse and human tissues
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gene expression database CSIOVDB (csibio.nus.edu.sg/CSIOVDB/CSIOVDB.html). HR, hazard ratio. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
206 D. Jia et al. / Cancer Letters 382 (2016) 203–214
Fig. 3. COL11A1 expression in cancer is associated with poor survival in multiple cancer types. (A) Survival z-scores in different cancer types associated with expression of COL11A1 mRNA. (B) Survival z-scores associated with
mRNA expression of different collagen genes. The data were obtained from the PREdiction of Clinical Outcomes from Genomic Proﬁles (PRECOG) database (precog.stanford.edu).
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revealed that COL11A1 is expressed in cartilage and collagen-
producing cells in the eye and brain, with negligible levels in most
other tissues that have been proﬁled including mesenchymal stem
cells in the bone marrow, muscle, and fat (data not shown).
Comparison of COL11A1 expression in 17931 cancers and 3503
normal tissues (U133Plus2 platform) and 9258 cancers and
4087 normal tissues (U133A platform) using the Gene Expression
across Normal and Tumor tissue (GENT) portal [35] revealed that
COL11A1 mRNA is elevated in most cancers in comparison to their
corresponding normal tissues (Fig. 4A). In some cancers, COL11A1
was ranked among the most statistically signiﬁcant differentially
expressed genes when cancer and its corresponding normal tissue
were compared. For example, comparison of cancer and normal
tissues in The Cancer Genome Atlas (TCGA) datasets for colon cancer
and invasive breast cancer ranked COL11A1 as the ﬁrst and thirdmost
differentially expressed gene, respectively (Fig. S3).
As many collagens and collagen-remodeling genes are fre-
quently upregulated in ﬁbroblast activation associated with
inﬂammation and ﬁbrosis in the absence of cancer, use of these genes
as therapeutic targets in cancer could be problematic. Analysis of
expression proﬁle datasets show that levels of COL11A1 mRNA in
inﬂamed colonic tissue from inﬂammatory bowel disease and ﬁ-
brotic lung tissues are not signiﬁcantly different from those in
corresponding unaffected colon and lung and that COL11A1 levels
associated with colon inﬂammation and lung ﬁbrosis are minimal
and markedly different from those associated with colon and lung
cancers (Fig. 4B). In contrast, levels of ACTA2, the gene encoding the
prototypical marker of myoﬁbroblast differentiation, αSMA, is ex-
pressed at similar levels in cancers and inﬂamed or ﬁbrotic tissues
(Fig. 4B).
A consistent set of genes is co-expressed with COL11A1 across
different cancers
To better understand the biology of cancers with high levels of
COL11A1, we identiﬁed genes that most closely correlate with
COL11A1 mRNA expression in 13 TCGA datasets representing dif-
ferent cancer types. Spearman’s rank correlations between COL11A1
and its co-expressed genes for each cancer type were calculated.
The genes were then ranked based on the average correlation of each
gene across the 13 cancer types. The top 195 correlated genes were
selected based on an average correlation of >0.4 COL11A1-correlated
genes were then ranked based on the average of the absolute cor-
relation values (Table 1 and Table S2). The top 10% most highly
correlated genes in each cancer type are highlighted in pink (Table 1).
Notably, COL11A1-correlated genes with high average correlation
scores also tended to be among the top 10% highest scored genes
in each cancer type (indicated in pink in Table 1). In contrast, the
top 10% COL11A1-anticorrelated genes were not conserved across
these cancer types (Table S3). Some of the top ranked COL11A1-
anticorrelated genes in individual cancer types were associated with
normal functions of these organs suggesting that they may repre-
sent normal tissue or a noninvasive tumor component. For example,
the ovarian cancer top 100 COL11A1-anticorrelated genes (Table S3)
present in the GSE12172 ovarian cancer dataset were primarily ex-
pressed in ovarian tumors of low malignant potential (Fig. S4).
Pan-cancer COL11A1-correlated genes are induced in CAFs
Consistent with the induced expression of COL11A1 in the in vitro
co-culture model (Fig. 1D), the average expression of the pan-
cancer COL11A1-correlated gene set was signiﬁcantly induced in
mesenchymal stem cells and normal ovarian ﬁbroblasts co-cultured
with ovarian cancer cells but not with normal ovarian epithelial cells
(Fig. S5). Since epithelial cells were not proﬁled in this experi-
ment, it is unknown if ﬁbroblasts also induce expression of the pan-
cancer COL11A1-correlated genes in epithelial cells. This is relevant
because several of the 195 pan-cancer COL11A1-correlated genes have
been shown to play a role in EMT [42] and malignant cells under-
going EMT have been proposed as one possible source of CAFs [44].
To determine if the pan-cancer COL11A1-correlated gene set is pref-
erentially expressed in cancer cells undergoing EMT or in host-
derived ﬁbroblasts, we used the e-mtab-991 public transcription
proﬁle dataset of primary patient-derived colon cancers and their
patient-derived xenografts (PDX) in nude mice [39]. Presumably, in
PDX samples, fast-proliferating human cancer cells continued to grow
in mice while slow-proliferating human CAFs were lost and even-
tually replaced by mouse ﬁbroblasts, which can be distinguished
from human cells by species-speciﬁc gene probes [39]. GeneSet clus-
tering analysis showed that most of the pan-cancer COL11A1-
correlated genes had diminished levels in PDX samples in comparison
to primary cancers (Fig. 5A), suggesting that the genes are en-
riched in the CAFs rather than in the cancer cells. However, it is also
possible that the pan-cancer COL11A1-correlated genes are ex-
pressed in epithelial cells in primary colon tumors but become
silenced upon adaptation of human cancer cells to the mouse mi-
croenvironment. Thus, we conducted GeneSet clustering analysis
of the primary ovarian cancer dataset GSE40595 in which ovarian
CAFs and epithelial cancer cells were isolated by laser-capture mi-
crodissection [40]. The pan-cancer COL11A1-correlated genes were
preferentially expressed in CAFs in this dataset (Fig. 5B).
In addition to CAFs, immune cells are a major component of the
tissue microenvironment. To exclude the possibility that the pan-
cancer COL11A1-correlated gene set represents immune cells in the
tumor microenvironment, we used the expression proﬁle of 230
mouse hematopoietic cell types generated by the Immunological
Genome Project (ImmGen) compendium [45]. In addition to he-
matopoietic cell lineages, the dataset contains expression proﬁles
of skin ﬁbroblasts and ﬁbroblasts residing in the thymus, lymph
nodes, and spleen. The pan-cancer COL11A1-correlated gene set was
highly represented in ﬁbroblasts but not in hematopoietic cell lin-
eages (Fig. 5C).
CAFs have a different expression proﬁle than normal ﬁbro-
blasts. Moﬃtt and colleagues deﬁned a 23-gene signature of ‘normal
stroma’ and a 25-gene signature of ‘activated stroma’ [46] using non-
negative matrix factorization for virtual microdissection of primary
and metastatic pancreatic ductal cancer samples into cell subsets
with prognostic and biologic relevance. None of the 23 (0%) ‘normal
stroma’ genes in contrast to 18 of 25 (72%) ‘activated stroma’ genes
were present in the COL11A1-correlated gene set, respectively
(Fig. 5D), suggesting that the COL11A1-correlated gene set repre-
sents CAFs.
Biological processes associated with ﬁbroblast activation in cancer
The remarkable uniformity of COL11A1-correlated genes across
13 different cancer types suggests involvement of these genes in
common biological processes that are independent of the organ site
and of the phenotypic and genetic diversity observed in individu-
al cancer types. To gain insight into the biology of this conserved
gene set, we conducted several analyses that identiﬁed overlap
between the 195 pan-cancer COL11A1-correlated genes and genes
in various datasets with characterized biological features. The Gene
Ontology (GO) Biological Process (BP) analysis revealed that the pan-
cancer COL11A1-correlated genes are primarily involved in
extracellular matrixmodiﬁcation and collagen remodeling (Table S4).
Additionally, we used SABiosciences array gene tables, which consist
of literature-based curatedmolecular pathways where each pathway
was represented by 84 genes. Analysis of gene overlap between
the pan-cancer COL11A1-correlated gene set and genes represen-
tative of 67 different pathways in SABiosciences arrays showed the
largest overlap for pathways associated with extracellular matrix,
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Fig. 4. Increased expression of COL11A1 in cancer and low expression in normal tissues, inﬂammation and ﬁbrosis. (A) Comparison of COL11A1 mRNA expression in normal tissues and corresponding cancers. Box plots for two
different platforms (U133Plus2 and U133A) were generated using datasets and software available through the Gene Expression across Normal and Tumor tissue (GENT) portal (medical-genome.kribb.re.kr/GENT). The y axis
shows log2 mRNA levels. Average expression levels in normal tissues and cancer tissues are indicated by vertical dotted green and red lines, respectively. (B) COL11A1 and ACTA2 mRNA expression in normal, inﬂammatory and
ﬁbrotic conditions in comparison to cancer. The graphs were generated using the public R2 MegaSampler software (hgserver1.amc.nl/cgi-bin/r2/main.cgi) for the processing and normalization of individual datasets imported
from the Gene Expression Omnibus (u133p2, MAS5.0 platform). The number of samples in each GSE dataset is indicated in parentheses. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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Table 1
COL11A1-correlated genes (Spearman’s rank correlation) across 13 different TCGA carcinoma types, each represented by >100 primary tumors from therapy-naive patients.
Pink denotes the top 10% COL11A1-correlated genes in each individual carcinoma type. Rectangles denote genes frequently used as markers of activated CAFs.
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Fig. 5. The pan-cancer COL11A1-correlated gene set is expressed in CAFs and associated with poor patient survival in multiple cancer types. (A) GeneSet expression clustering analysis of 40 primary colon cancer samples and
75 patient-derived xenograft (PDX) samples in the e-mtab-991 dataset using the pan-cancer COL11A1-correlated genes. (B) GeneSet expression clustering analysis of laser-microdissected ovarian cancer epithelial cells (32 samples)
and CAFs (31 samples) in high grade serous ovarian cancer in the GSE40595 dataset using the pan-cancer COL11A1-correlated genes. The Euclidean distance clustering analysis heatmaps in (A) and (B) were generated using the
public R2 GeneSet Clustering Analysis tool (hgserver1.amc.nl/cgi-bin/r2/main.cgi). (C) Expression of the pan-cancer COL11A1-correlated genes mapped on the transcriptome of individual murine hematopoietic and stromal cell
types in the ImmGene project (immgen.com). The plot was generated using MyGeneset tool (rstats.immgen.org/MyGeneSet). Black dots represent mRNA levels (y axis) of 186 pan-cancer COL11A1-correlated genes (9 genes
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deﬁned by Moﬃtt et al. (E) Unweighted meta z-scores of 191 COL11A1-correlated genes (4 genes were not available in the PRECOG database) were compared with those of all genes (total 23,287 genes) in the PRECOG database
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ﬁbrosis, osteogenesis, wound healing, EMT, cardiovascular disease,
and transforming growth factor β (TGFβ) signaling (Table S5).
COL11A1-correlated gene set enrichment analysis of chemical and
genetic perturbations (CGP) showed themost signiﬁcant overlapwith
genes up-regulated in association with cancer invasiveness, ad-
vanced stage, stromal cell stemness, and epithelial-mesenchymal
transition (EMT) (Table S6). The uniformity of the COL11A1-correlated
genes across different cancers might also indicate that these genes
are regulated by a common mechanism. Ingenuity Pathway Anal-
ysis showed that transforming growth factor beta 1 (TGFB1) is the
most strongly associated upstream regulator of the pan-cancer
COL11A1-correlated genes (Table S7).
COL11A1-correlated genes are associated with poor patient survival
and represent potential therapeutic targets
To determine whether the pan-cancer COL11A1-correlated gene
set is associated with patient survival in the ~18,000 cases of liquid
and solid malignancies in the PRECOG dataset [36], we compared
survival z-scores for the 195 pan-cancer COL11A1-correlated genes
with the survival z-scores for all genes in the dataset. This analy-
sis showed that expression of the pan-cancer COL11A1-correlated
gene set is signiﬁcantly associated with poor survival (Fig. 5E).
Expression proﬁle analyses have identiﬁed a mesenchymal mo-
lecular subtype of cancer associated with poor survival in multiple
cancers including ovarian [47], pancreatic [46], gastric [48] and colon
[49]. In colon cancer, it has been shown that the mesenchymal mo-
lecular subtype, which constitutes approximately 23% of colon
cancers, has no signiﬁcant enrichment for targetable mutations or
copy number changes in candidate driver genes [49]. Even if future
research identiﬁes targetable events in cancer cells of the mesen-
chymal subtype, it is predicted that enrichment in CAFs and excessive
ECM deposition will reduce therapeutic eﬃcacy by creating a phys-
ical barrier for drug transport. Thus, simultaneous targeting of CAFs
and cancer cells may be necessary for chemotherapeutic accessibility.
To identify therapies that preferentially target activated CAFs
and spare normal tissues, we combined drug target searches with
expression proﬁle datasets in cancers and normal tissues. Ingenu-
ity Pathway Analysis and searches of the Clinicaltrials.gov
(clinicaltrials.gov) and ChEMBL [50] (ebi.ac.uk/chembl) databases
revealed that, of the 195 pan-cancer COL11A1-correlated genes, 16
are targets of drugs used in clinical trials (Table S8) and 30 are targets
of bioactive compounds (Table S9).
To test whether any of the drug/bioactive compound target genes
in Tables S8 and S9 are exclusively expressed in activated CAFs, we
determined the expression levels of each gene in normal tissues in
the GTEx database [43] and in normal vs. cancer tissues in the GENT
database [35]. Additionally, to test whether selected genes were ex-
clusively overexpressed in cancer tissues and not in non-cancer
associated pathologies such as inﬂammation and ﬁbrosis, we com-
pared expression of these genes in normal tissues, inﬂamed/
ﬁbrotic tissues and cancer tissues of the colon and lung. Unlike
COL11A1, which has restricted expression in normal tissues (Fig. S2)
and is highly elevated in cancer vs. normal tissues (Fig. 4A) and in
cancer vs. inﬂamed/ﬁbrotic tissues (Fig. 4B) most of the target genes
were expressed at high levels in at least one normal tissue and/or
exhibited equivalent expression levels in cancers vs. normal tissues,
and cancers vs. inﬂamed/ﬁbrotic tissues. One example of this pattern
of expression is CTGF (Figs. S6 and S7). However, FN1,MMP13,MMP14,
FAP, LOX and COL1A2 exhibited restricted expression in normal tissues
and elevated expression in cancer vs. normal tissues. One example
of this pattern of expression is FAP (Figs. S8 and S9). Among FN1,
MMP13, MMP14, FAP, LOX and COL1A2, FAP was also differentially
expressed between inﬂamed/ﬁbrotic tissues and cancer tissues al-
though this difference in expression was not as prominent as for
COL11A1 (compare Fig. S9B and Fig. 4B).
Discussion
Whereas in the past most therapeutic approaches have focused
on the cancer cell and its genetic alterations, it is becoming appar-
ent that the microenvironment plays an equally important role in
cancer evolution. We now recognize that the cancer stroma not only
serves as a scaffold for tissue organization and integrity but also pro-
vides key biomechanical andmolecular signals that can affect various
aspects of cancer growth and biology, including proliferation, sur-
vival, metabolism, stem cell fate, and response to chemotherapy
[51,52]. As the genetically stable subpopulations of the cancer mi-
croenvironment are increasingly recognized as potentially effective
therapeutic targets, a comprehensive deﬁnition of their molecular
characteristics will be a prerequisite for the development of more
precise and less toxic therapies. Currently, there are no reliable
methods to distinguish activated CAFs from non-activated CAFs,
which although frequently abundant within cancers do not neces-
sarily contribute to adverse outcome. We identiﬁed COL11A1 among
the top differentially expressed genes in multiple cancer types when
cancer tissues and their corresponding normal tissues were com-
pared. We showed that an increase in COL11A1 expression is
associated with progression and poor survival in most cancer types.
COL11A1 is a particularly attractive therapeutic target because of its
restricted expression in normal tissues and non-cancer condi-
tions, such as inﬂammation and ﬁbrosis.
The identiﬁcation of a highly conserved set of genes associated
with COL11A1 expression in breast, lung, pancreas, stomach, urinary
bladder, colon, thyroid, cervix, head and neck, thyroid, ovary, and
prostate cancers was somewhat surprising in light of the genetic
and phenotypic diversity among these cancer types. The con-
served expression signature indicates that the reaction of stromal
tissues to invading epithelial cancer cells may be similar regard-
less of the organ of origin or genetic alterations. This has signiﬁcant
implications for the development of pan-cancer therapeutic strat-
egies. Our analysis of potential upstream regulators of the pan-
cancer COL11A1-correlated genes revealed TGFB1 as the most likely
candidate. Dysregulation of TGFβ signaling is recognized as themain
driver of ﬁbroblast activation and represents the most logical ther-
apeutic target [53]. In immortalized normal ovary ﬁbroblast cell
culture, recombinant TGFB1 has been shown to upregulate expres-
sion of COL11A1 and several other COL11A1-correlated genes; this
effect was abrogated by the TGFβ receptor inhibitor A83-01 [32].
However, the pleiotropic nature of TGFβ signaling carries the risk
of adverse effects in patients [54]. In order to abrogate ﬁbroblast
activation without the negative effects of pan-TGFβ therapy, it will
be necessary to design therapies for more speciﬁc targets.
Sixteen of the 195 pan-cancer COL11A1-correlated genes are
targets of drugs in clinical trials. These targets include CTGF, a
matricellular protein involved in myoﬁbroblast formation in cancer
as a binding factor of ﬁbronectin and a downstream mediator of
TGFβ. A clinical trial (clinicaltrials.gov; NCT02210559) is currently
enrolling patients with unresectable pancreatic cancer to test a com-
bination of conventional chemotherapy and FG-3019, the human
monoclonal antibody that interferes with the action of CTGF. Our
expression analyses, consistent with the published literature (re-
viewed in Ref. [55]), show that CTGF is expressed at similar levels
in normal tissues and cancers and therefore unlikely to be a safe
therapeutic target for cancer treatment. In contrast, targets such as
FN1, FAP, MMP13, LOX and COL2A1 aremarkedly increased in cancer/
inﬂammation/ﬁbrosis compared to normal tissues and are thus
predicted to have a better safety proﬁle than agents targeting CTGF.
Our assessment is consistent with the published moderate and re-
versible toxicity of the FN1-targeting monoclonal antibody-cytokine
fusion protein L19-IL2, which is in a phase I/II study for patients
with solid cancers (clinicaltrials.gov; NCT01058538) [56,57]. Our ex-
pression analyses show that one of the targets of bioactive
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compounds, FAP, has low expression in normal tissues and also lower
expression in inﬂamed/ﬁbrotic tissues than in cancer. Yet, this dif-
ference in expression may not be suﬃcient for speciﬁc targeting of
activated CAFs as studies in mouse models have shown that de-
pletion of the FAP+ stroma can induce toxicity due to expression
of FAP in themesenchymal cells of bonemarrow,muscle and adipose
tissue [58,59]. Future efforts to speciﬁcally target activated CAFs can
be improved by designing novel therapies to target genes that exhibit
restricted expression in nonmalignant tissues. When considering
COL11A1 as a cancer-speciﬁc biomarker and therapeutic target, it
is important to note that several normal tissues express COL11A1.
The potential side effects of COL11A1 targeting can be predicted
based on the phenotypes of mice and humans expressing mutant
nonfunctional forms of COL11A1. A homozygous truncating muta-
tion of COL11A1 in mice results in poorly formed cartilage [60],
while human COL11A1 mutations are associated with articular
hypermobility, dermal hyperelasticity and widespread tissue fra-
gility [61]. Of note, these collagenopathies are associated with the
absence of COL11A1 function throughout development and are un-
likely to manifest upon transient targeting of COL11A1 in adults.
Additionally, since COL11A1 and many of the pan-cancer COL11A1-
coexpressed genes have multiple tissue-speciﬁc mRNA splicing
isoforms, it will be valuable for future targeting purposes to deter-
mine if any mRNA isoforms are speciﬁcally expressed in activated
CAFs [62].
Acknowledgments
We thank S. Swartwood (Biobank and Translational Research
Core) for in situ hybridization; F. Chung (Pathology Service) for im-
munohistochemistry; G.Martins (Flow Cytometry Core) for assistance
with FACS analysis; and K. Daniels for assistance with manuscript
preparation. SO is supported by the Oﬃce of the Assistant Secre-
tary of Defense for Health Affairs through the Ovarian Cancer
Research Program Award No. W81XWH-14-1-0107 andW81XWH-
16-1-0190, the National Cancer Institute grants R21CA194626-01
and 1R01CA208753-01, and the Cantor-UCLAWomen’s Health Center
Executive Advisory Board & NCATS UCLA Clinical and Transla-
tional Science Institute grant UL1TR000124. BYK is supported by
the American Cancer Society Early Detection Professorship Grant
(SIOP-06-258-01-COUN). BYK, SO, KL and WRW are supported by
the Ovarian Cancer Research Fund Program Project Development
Award and DJC is supported by the Ovarian Cancer Research Fund
Ann Shreiber Mentored Investigator Award. Opinions, interpreta-
tions, conclusions and recommendations are those of the authors
and are not necessarily endorsed by the funding agencies.
Conﬂict of interest
The authors declare no conﬂict of interest.
Appendix:: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.canlet.2016.09.001.
References
[1] R. Kalluri, M. Zeisberg, Fibroblasts in cancer, Nat. Rev. Cancer 6 (2006) 392–401.
[2] B. Hinz, S.H. Phan, V.J. Thannickal, M. Prunotto, A. Desmouliere, J. Varga, et al.,
Recent developments in myoﬁbroblast biology: paradigms for connective tissue
remodeling, Am. J. Pathol. 180 (2012) 1340–1355.
[3] A. Desmouliere, C. Guyot, G. Gabbiani, The stroma reaction myoﬁbroblast:
a key player in the control of tumor cell behavior, Int. J. Dev. Biol. 48 (2004)
509–517.
[4] H.E. Barker, T.R. Cox, J.T. Erler, The rationale for targeting the LOX family in
cancer, Nat. Rev. Cancer 12 (2012) 540–552.
[5] M.J. Paszek, N. Zahir, K.R. Johnson, J.N. Lakins, G.I. Rozenberg, A. Gefen, et al.,
Tensional homeostasis and the malignant phenotype, Cancer Cell 8 (2005)
241–254.
[6] P.P. Provenzano, D.R. Inman, K.W. Eliceiri, J.G. Knittel, L. Yan, C.T. Rueden, et al.,
Collagen density promotes mammary tumor initiation and progression, BMC
Med. 6 (2008) 11.
[7] D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression and
metastasis, Nat. Med. 19 (2013) 1423–1437.
[8] R.K. Jain, Normalizing tumor microenvironment to treat cancer: bench to
bedside to biomarkers, J. Clin. Oncol. 31 (2013) 2205–2218.
[9] W. Qiu, M. Hu, A. Sridhar, K. Opeskin, S. Fox, M. Shipitsin, et al., No evidence
of clonal somatic genetic alterations in cancer-associated ﬁbroblasts from human
breast and ovarian carcinomas, Nat. Genet. 40 (2008) 650–655.
[10] J.N. Arnold, L. Magiera, M. Kraman, D.T. Fearon, Tumoral immune suppression
by macrophages expressing ﬁbroblast activation protein-alpha and heme
oxygenase-1, Cancer Immunol. Res. 2 (2014) 121–126.
[11] C. Feig, J.O. Jones, M. Kraman, R.J. Wells, A. Deonarine, D.S. Chan, et al., Targeting
CXCL12 from FAP-expressing carcinoma-associated ﬁbroblasts synergizes with
anti-PD-L1 immunotherapy in pancreatic cancer, Proc. Natl. Acad. Sci. U.S.A.
110 (2013) 20212–20217.
[12] M. Kraman, P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, J.O. Jones, et al.,
Suppression of antitumor immunity by stromal cells expressing ﬁbroblast
activation protein-alpha, Science 330 (2010) 827–830.
[13] A. Lo, L.C. Wang, J. Scholler, J. Monslow, D. Avery, K. Newick, et al., Tumor-
promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells,
Cancer Res. 75 (2015) 2800–2810.
[14] M. Loeﬄer, J.A. Kruger, A.G. Niethammer, R.A. Reisfeld, Targeting tumor-
associated ﬁbroblasts improves cancer chemotherapy by increasing intratumoral
drug uptake, J. Clin. Invest. 116 (2006) 1955–1962.
[15] P.P. Provenzano, C. Cuevas, A.E. Chang, V.K. Goel, D.D. Von Hoff, S.R. Hingorani,
Enzymatic targeting of the stroma ablates physical barriers to treatment of
pancreatic ductal adenocarcinoma, Cancer Cell 21 (2012) 418–429.
[16] B.C. Ozdemir, T. Pentcheva-Hoang, J.L. Carstens, X. Zheng, C.C. Wu, T.R. Simpson,
et al., Depletion of carcinoma-associated ﬁbroblasts and ﬁbrosis induces
immunosuppression and accelerates pancreas cancer with reduced survival,
Cancer Cell 25 (2014) 719–734.
[17] M.R. Junttila, F.J. de Sauvage, Inﬂuence of tumour micro-environment
heterogeneity on therapeutic response, Nature 501 (2013) 346–354.
[18] A. Kawase, G. Ishii, K. Nagai, T. Ito, T. Nagano, Y. Murata, et al., Podoplanin
expression by cancer associated ﬁbroblasts predicts poor prognosis of lung
adenocarcinoma, Int. J. Cancer 123 (2008) 1053–1059.
[19] M.J. Ronty, S.K. Leivonen, B. Hinz, A. Rachlin, C.A. Otey, V.M. Kahari, et al.,
Isoform-speciﬁc regulation of the actin-organizing protein palladin during
TGF-beta1-inducedmyoﬁbroblast differentiation, J. Invest. Dermatol. 126 (2006)
2387–2396.
[20] T.A. Brentnall, L.A. Lai, J. Coleman, M.P. Bronner, S. Pan, R. Chen, Arousal of
cancer-associated stroma: overexpression of palladin activates ﬁbroblasts to
promote tumor invasion, PLoS ONE 7 (2012) e30219.
[21] O. De Wever, Q.D. Nguyen, L. Van Hoorde, M. Bracke, E. Bruyneel, C. Gespach,
et al., Tenascin-C and SF/HGF produced by myoﬁbroblasts in vitro provide
convergent pro-invasive signals to human colon cancer cells through RhoA and
Rac, FASEB J. 18 (2004) 1016–1018.
[22] K. Pietras, J. Pahler, G. Bergers, D. Hanahan, Functions of paracrine PDGF
signaling in the proangiogenic tumor stroma revealed by pharmacological
targeting, PLoS Med. 5 (2008) e19.
[23] N. Erez, M. Truitt, P. Olson, S.T. Arron, D. Hanahan, Cancer-associated ﬁbroblasts
are activated in incipient neoplasia to orchestrate tumor-promoting
inﬂammation in an NF-kappaB-dependent manner, Cancer Cell 17 (2010)
135–147.
[24] H. Sugimoto, T.M. Mundel, M.W. Kieran, R. Kalluri, Identiﬁcation of ﬁbroblast
heterogeneity in the tumor microenvironment, Cancer Biol. Ther. 5 (2006)
1640–1646.
[25] F. Vazquez-Villa, M. Garcia-Ocana, J.A. Galvan, J. Garcia-Martinez, C.
Garcia-Pravia, P. Menendez-Rodriguez, et al., COL11A1/(pro)collagen 11A1
expression is a remarkable biomarker of human invasive carcinoma-associated
stromal cells and carcinoma progression, Tumor Biol. 36 (2015) 2213–2222.
[26] Z. Raglow, S.M. Thomas, Tumor matrix protein collagen XIalpha1 in cancer,
Cancer Lett. 357 (2015) 448–453.
[27] R.J. Wenstrup, S.M. Smith, J.B. Florer, G. Zhang, D.P. Beason, R.E. Seegmiller, et al.,
Regulation of collagen ﬁbril nucleation and initial ﬁbril assembly involves
coordinate interactions with collagens V and XI in developing tendon, J. Biol.
Chem. 286 (2011) 20455–20465.
[28] S.M. Smith, D.E. Birk, Focus on molecules: collagens V and XI, Exp. Eye Res. 98
(2012) 105–106.
[29] P. Farmer, H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, V. Becette, et al., A
stroma-related gene signature predicts resistance to neoadjuvant chemotherapy
in breast cancer, Nat. Med. 15 (2009) 68–74.
[30] W.Y. Cheng, J.J. Kandel, D.J. Yamashiro, P. Canoll, D. Anastassiou, A multi-cancer
mesenchymal transition gene expression signature is associated with prolonged
time to recurrence in glioblastoma, PLoS ONE 7 (2012) e34705.
[31] J. Boguslawska, H. Kedzierska, P. Poplawski, B. Rybicka, Z. Tanski, A.
Piekielko-Witkowska, Expression of genes involved in cellular adhesion and
ECM-remodelling correlates with poor survival of renal cancer patients, J. Urol.
195 (2016) 1892–1902.
[32] D.J. Cheon, Y. Tong, M.S. Sim, J. Dering, D. Berel, X. Cui, et al., A collagen-
remodeling gene signature regulated by TGF-beta signaling is associated with
213D. Jia et al. / Cancer Letters 382 (2016) 203–214
metastasis and poor survival in serous ovarian cancer, Clin. Cancer Res. 20 (2014)
711–723.
[33] Y.H.Wu, T.H. Chang, Y.F. Huang, H.D. Huang, C.Y. Chou, COL11A1 promotes tumor
progression and predicts poor clinical outcome in ovarian cancer, Oncogene
33 (2014) 3432–3440.
[34] J.A. Beach, P.J. Aspuria, D.J. Cheon, K. Lawrenson, H. Agadjanian, C.S. Walsh, et al.,
Sphingosine kinase 1 is required for TGF-beta mediated ﬁbroblast-to-
myoﬁbroblast differentiation in ovarian cancer, Oncotarget 7 (2016) 4167–4182.
[35] G. Shin, T.W. Kang, S. Yang, S.J. Baek, Y.S. Jeong, S.Y. Kim, GENT: gene expression
database of normal and tumor tissues, Cancer Inform. 10 (2011) 149–157.
[36] A.J. Gentles, S.V. Bratman, L.J. Lee, J.P. Harris, W. Feng, R.V. Nair, et al., Integrating
tumor and stromal gene expression signatures with clinical indices for survival
stratiﬁcation of early-stage non-small cell lung cancer, J. Natl. Cancer Inst. 107
(2015).
[37] E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, et al., The cBio
cancer genomics portal: an open platform for exploringmultidimensional cancer
genomics data, Cancer Discov. 2 (2012) 401–404.
[38] T.Z. Tan, H. Yang, J.R. Ye, J. Low, M. Choolani, D.S.P. Tan, et al., CSIOVDB: a
microarray gene expression database of epithelial ovarian cancer subtype,
Oncotarget 6 (2015) 43843–43852.
[39] S. Julien, A. Merino-Trigo, L. Lacroix, M. Pocard, D. Goere, P. Mariani, et al.,
Characterization of a large panel of patient-derived tumor xenografts
representing the clinical heterogeneity of human colorectal cancer, Clin. Cancer
Res. 18 (2012) 5314–5328.
[40] T.L. Yeung, C.S. Leung, K.K. Wong, G. Samimi, M.S. Thompson, J. Liu, et al.,
TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived
versican in the tumor microenvironment, Cancer Res. 73 (2013) 5016–5028.
[41] K. Lawrenson, B. Grun, N. Lee, P. Mhawech-Fauceglia, J. Kan, S. Swenson, et al.,
NPPB is a novel candidate biomarker expressed by cancer-associated ﬁbroblasts
in epithelial ovarian cancer, Int. J. Cancer 136 (2015) 1390–1401.
[42] T.Z. Tan, Q.H. Miow, Y. Miki, T. Noda, S. Mori, R.Y. Huang, et al., Epithelial-
mesenchymal transition spectrum quantiﬁcation and its eﬃcacy in deciphering
survival and drug responses of cancer patients, EMBO Mol. Med. 6 (2014)
1279–1293.
[43] G. Consortium, The Genotype-Tissue Expression (GTEx) project, Nat. Genet. 45
(2013) 580–585.
[44] R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition,
J. Clin. Invest. 119 (2009) 1420–1428.
[45] T. Shay, J. Kang, Immunological Genome Project and systems immunology,
Trends Immunol. 34 (2013) 602–609.
[46] R.A. Moﬃtt, R. Marayati, E.L. Flate, K.E. Volmar, S.G. Loeza, K.A. Hoadley, et al.,
Virtual microdissection identiﬁes distinct tumor- and stroma-speciﬁc subtypes
of pancreatic ductal adenocarcinoma, Nat. Genet. 47 (2015) 1168–1178.
[47] R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, et al.,
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma,
J. Clin. Invest. 123 (2013) 517–525.
[48] R. Cristescu, J. Lee, M. Nebozhyn, K.M. Kim, J.C. Ting, S.S. Wong, et al., Molecular
analysis of gastric cancer identiﬁes subtypes associated with distinct clinical
outcomes, Nat. Med. 21 (2015) 449–456.
[49] J. Guinney, R. Dienstmann, X. Wang, A. de Reynies, A. Schlicker, C. Soneson, et al.,
The consensus molecular subtypes of colorectal cancer, Nat. Med. 21 (2015)
1350–1356.
[50] A.P. Bento, A. Gaulton, A. Hersey, L.J. Bellis, J. Chambers, M. Davies, et al., The
ChEMBL bioactivity database: an update, Nucleic Acids Res. 42 (2014) D1083–
D1090.
[51] M. Egeblad, M.G. Rasch, V.M. Weaver, Dynamic interplay between the collagen
scaffold and tumor evolution, Curr. Opin. Cell Biol. 22 (2010) 697–706.
[52] I. Malanchi, A. Santamaria-Martinez, E. Susanto, H. Peng, H.A. Lehr, J.F. Delaloye,
et al., Interactions between cancer stem cells and their niche govern metastatic
colonization, Nature 481 (2012) 85–89.
[53] J. Massague, TGFbeta signalling in context, Nat. Rev. Mol. Cell Biol. 13 (2012)
616–630.
[54] E.C. Connolly, J. Freimuth, R.J. Akhurst, Complexities of TGF-beta targeted cancer
therapy, Int. J. Biol. Sci. 8 (2012) 964–978.
[55] S. Kubota, M. Takigawa, Cellular and molecular actions of CCN2/CTGF and its
role under physiological and pathological conditions, Clin. Sci. 128 (2015)
181–196.
[56] M. Johannsen, G. Spitaleri, G. Curigliano, J. Roigas, S. Weikert, C. Kempkensteffen,
et al., The tumour-targeting human L19-IL2 immunocytokine: preclinical safety
studies, phase I clinical trial in patients with solid tumours and expansion into
patients with advanced renal cell carcinoma, Eur. J. Cancer 46 (2010) 2926–
2935.
[57] T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pﬂugfelder,
et al., A dose-escalation and signal-generating study of the immunocytokine
L19-IL2 in combination with dacarbazine for the therapy of patients with
metastatic melanoma, Clin. Cancer Res. 17 (2011) 7732–7742.
[58] E. Tran, D. Chinnasamy, Z. Yu, R.A. Morgan, C.C. Lee, N.P. Restifo, et al.,
Immune targeting of ﬁbroblast activation protein triggers recognition of
multipotent bone marrow stromal cells and cachexia, J. Exp. Med. 210 (2013)
1125–1135.
[59] E.W. Roberts, A. Deonarine, J.O. Jones, A.E. Denton, C. Feig, S.K. Lyons, et al.,
Depletion of stromal cells expressing ﬁbroblast activation protein-alpha from
skeletal muscle and bone marrow results in cachexia and anemia, J. Exp. Med.
210 (2013) 1137–1151.
[60] Y. Li, D.A. Lacerda, M.L. Warman, D.R. Beier, H. Yoshioka, Y. Ninomiya, et al., A
ﬁbrillar collagen gene, Col11a1, is essential for skeletal morphogenesis, Cell 80
(1995) 423–430.
[61] J. Spranger, The type XI collagenopathies, Pediatr. Radiol. 28 (1998) 745–750.
[62] U.H. Weidle, D. Maisel, S. Klostermann, E.H. Weiss, M. Schmitt, Differential
splicing generates new transmembrane receptor and extracellular matrix-related
targets for antibody-based therapy of cancer, Cancer Genomics Proteomics 8
(2011) 211–226.
214 D. Jia et al. / Cancer Letters 382 (2016) 203–214
